文献速递甲状腺疾病

帕博利珠单抗诱发的甲状腺炎:全面临床综述及对潜在相关机制的探讨

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该单中心回顾性队列研究纳入93例接受至少一次帕博利珠单抗输注的晚期癌症患者,观察到13例(14%)甲状腺免疫相关不良事件,甲状腺炎7例(54%)中4例恢复,3例新发甲减,3例已知甲减者左甲状腺素剂量需加倍;机制可能涉及T细胞、NK细胞和/或单核细胞通路,似不依赖甲状腺自身抗体。

要点

  • 帕博利珠单抗治疗患者中甲状腺免疫相关不良事件发生率为14%(13/93)。
  • 甲状腺炎最常见,7例中4例恢复;甲减新发3例,已知甲减者3例需左甲状腺素剂量加倍。
  • 甲状腺破坏机制似不依赖甲状腺自身抗体,可能涉及T细胞、NK细胞和/或单核细胞通路。

核心结论

  • 接受帕博利珠单抗治疗的癌症患者中甲状腺功能障碍常见,可逆性破坏性甲状腺炎和显性甲减是最常见的临床表现。
  • 甲状腺破坏机制似不依赖甲状腺自身抗体,可能包括T细胞、NK细胞和/或单核细胞介导的通路。
  • 因甲状腺是抗PD-1治疗的常见靶点,治疗难治性甲状腺癌患者可能是该治疗的理想候选者。

研究设计与样本

  • 单中心、回顾性队列研究,纳入93例接受至少一次帕博利珠单抗输注的晚期癌症患者(年龄24至82岁,60%为男性)。
  • 回顾甲状腺检测结果和甲状腺影像学检查,并进行外周血10色流式细胞术检测。

主要发现

  • 观察到13例(14%)甲状腺免疫相关不良事件。
  • 甲状腺炎发生于7例患者(54%),其中4例恢复。
  • 3例患者新发显性或亚临床甲减。
  • 3例有已知甲减病史的患者左甲状腺素剂量需加倍。
  • 甲状腺过氧化物酶抗体阳性见于少数患者[4/13(31%)],甲状腺弥漫性18氟脱氧葡萄糖摄取增高见于多数患者[7/11(64%)]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid immune-related adverse events (irAEs) in patients treated with programmed death receptor-1 (PD-1) blockade are increasingly recognized as one of the most common adverse effects. Our aim was to determine the incidence and examine the potential mechanisms of anti-PD-1-induced thyroid irAEs. DESIGN: Single-center, retrospective cohort study. PATIENTS AND MEASUREMENTS: We studied 93 patients with advanced cancer (ages 24 to 82 years; 60% males) who received at least one infusion of pembrolizumab. Thyroid test results and thyroid imaging modalities were reviewed. Comprehensive 10-color flow cytometry of peripheral blood was performed. RESULTS: Thirteen (14%) thyroid irAEs were observed. Thyroiditis occurred in seven patients (54%), from which four recovered. New onset of hypothyroidism overt/subclinical developed in three patients. Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism. Thyroperoxidase antibodies were positive in the minority of the patients [4/13 (31%)] and diffuse increased 18fludeoxyglucose uptake of the thyroid gland was observed in the majority [7/11 (64%)] of patients. We observed more circulating CD56+CD16+ natural killer (NK) cells and an elevated HLA-DR surface expression in the inflammatory intermediate CD14+CD16+ monocytes in anti-PD-1-treated patients. CONCLUSIONS: Thyroid dysfunction is common in cancer patients treated with pembrolizumab. Reversible destructive thyroiditis and overt hypothyroidism are the most common clinical presentations. The mechanism of thyroid destruction appears independent of thyroid autoantibodies and may include T cell, NK cell, and/or monocyte-mediated pathways. Because the thyroid is a frequent target of anti-PD-1 therapies, patients with therapeutically refractory thyroid cancer may be ideal candidates for this treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017. PMID: 28609832. doi:10.1210/jc.2017-00448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。